Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma
Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from...
VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy
New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...
Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...
Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R/R DLBCL
Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss...
Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication...
Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment
China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical...
Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...
Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study...
Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G
Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence...
Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to...
Junshi Biosciences’ Senaparib Meets Primary Endpoint in Phase III Ovarian Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has declared that the Phase III FLAMES study...
Porton Pharma Solutions Expands with Biomacromolecules R&D and Manufacturing Center in Shanghai
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has initiated the construction of...
Blueray Med Secures Tens of Millions in Series A+ Financing for Advanced Laser Medicine Devices
Blueray Med, a leading high-end laser medicine device manufacturer based in Xi’an, has reportedly secured...
Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC
Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...
Legend Biotech Appoints Dr. Mythili Koneru as Chief Medical Officer to Lead Clinical Development
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the appointment of Dr. Mythili Koneru as...
Luye Pharma’s Bevacizumab Biosimilar Accepted for Review in Brazil by ANVISA
China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its...
Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers
The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have...
Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE
The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...
Bristol-Myers Squibb Launches Zeposia in China for Multiple Sclerosis Treatment
Global pharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced the market launch in China...
Hubei Implements Inter-Provincial VBP Tender Results for Pacemakers
The Hubei provincial Drug and Instrument Procurement Platform has issued a notice regarding the implementation...